Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the nearterm price movement of its stock are proven to ...

SAN DIEGO, July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024. In addition to the anticipated launch of the VAN, the national rollout of the CrossLink Life Sciences, LLC ("C ...

SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion of the FDA's review of this PAS within the next several weeks and anticipates an action ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

| --- | --- | --- | |---------------------------------------|-------|-------| | | | | | | | | | Heron Therapeutics Q1 Earnings Call | | | | May 7, 2024 | | | 2 4 3 Gross Margin improved to 76% for the quarter, up from 43% for the same period last year Select Financial Results Oncology Care Franchise Net Sales This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forwardlooking statements are based on management's ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer William Forbes - Executive Vice President, Chief Development Officer Kevin Warner - SVP of Medical Affairs strategy engagements David Barozzino - Vice President of Sales, Acute Care Conference Call Participants Serge Berlanger - Needham Carl Byrnes - Northland Capital Markets Tim Chiang - ...

Heron Therapeutics (HRTX) reported $34.67 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 17.1%. EPS of -$0.02 for the same period compares to -$0.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $32.5 million, representing a surprise of +6.68%. The company delivered an EPS surprise of +75.00%, with the consensus EPS estimate being -$0.08.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 75%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.15 per share when it actually produced a loss of $0.07, delivering a surprise of 53.33%.Over the last four quarters, the compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict ...

318509926.1 Exhibit 99.1 Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates SAN DIEGO, May 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates. "We are extremely pleased with our ability to improve the financial efficiency of the business by growing revenues ...